UNSPSC 51111739: Etoposide

This classification denotes an epipodophyllotoxin compound, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6PLQ3CP4P3. European Medicines Agency schedules Etoposide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07337MIG. Etoposide generally arises in the molecular formula C29H32O13.

UNSPSC 51111739 Etoposide, a Commodity code, nominally identifies a specific pharmaceutical product, but the recent state and local opportunities tagged under this code show substantial misalignment with the abstract scope. The solicitations posted under 51111739 span pharmaceuticals broadly — including naloxone, generic multi-source drugs, and over-the-counter products — rather than etoposide specifically. State and local issuing bodies using this code are procuring medical and first aid supplies for emergency response, pharmacy benefit programs, and health department operations. The work includes sealed competitive bidding for emergency supplies, requests for information to map direct-to-manufacturer contracting pathways, cooperative purchasing framework agreements for generic pharmaceuticals, and volume-based acquisitions of naloxone and drug deactivation systems. Buyers range across county health departments, fire departments, state health and human services agencies, and multistate cooperative purchasing alliances.

Activity is concentrated in Florida, Texas, and Minnesota, with participation in cooperative purchasing extending to additional jurisdictions including Oregon. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery (response deadline July 26, 2023); the City of Tampa's IFB 26P00145 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with estimated value of $700,000.00 and a certified Small Local Business Enterprise set-aside (response deadline March 13, 2026); Texas Health and Human Services Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription programs (posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposal due March 26, 2026. The code appears to function as a catch-all pharmaceutical taxonomy entry within state procurement systems, creating a mismatch between the nominal commodity and the actual procurement scope. Firms evaluating this code should recognize that opportunities are episodic, geographically scattered, and often solicited through cooperative purchasing or established emergency supply frameworks rather than one-off spot buys.